Article Sidebar

PDF (Tiếng Việt)
Published: 2024-12-12
Abstract Views: 16
Views PDF (Tiếng Việt): 8
DOI: https://doi.org/10.52163/yhc.v65iCD12.1843
Issue
Vol. 65 No. CĐ 12 - Bệnh viện Thủ Đức
Section
Articles
How to Cite
Hương, N. H. T., Quy, D. T., Khanh, T. H., & Hùng, N. T. (2024). 33. THE CLINICAL FEATURES OF NMDAR-ANTIBODY ENCEPHALITIS AT CHILDREN’S HOSPITAL 1. Vietnam Journal of Community Medicine, 65(CĐ 12 - Bệnh viện Thủ Đức). https://doi.org/10.52163/yhc.v65iCD12.1843

33. THE CLINICAL FEATURES OF NMDAR-ANTIBODY ENCEPHALITIS AT CHILDREN'S HOSPITAL 1

Nguyen Hoang Thien Huong1, Du Tuan Quy2, Truong Huu Khanh2, Nguyen Thanh Hung1,2
1 University of Health Sciences, Vietnam National University at Ho Chi Minh City
2 Children's Hospital 1

Main Article Content

Abstract

Background: N-methyl D aspartate receptor (NMDAR)-antibody encephalitis, is the most common form of autoimmune encephalitis in children, has now exceeded the incidence rate of infectious encephalitis according to the latest data in the United States and Europe. In southern Vietnam, particularly Ho Chi Minh City, we currently do not have much clinical data on this emerging disease. Therefore, we conducted this study to determine the clinical characteristics of NMDAR-antibody encephalitis at Children's Hospital 1. Methods: Prospective observational study from March 2020 to December 2022 at Children's Hospital 1. Results: NMDAR-antibody encephalitis was observed in 23 hospitalized children. The main clinical manifestations were mental symptoms (73.9%), cognitive disorders (69.6%), language changes (69.6%), abnormal movements (69.6%), and dyskinesia (65.2%). EEG was characterized by delta brush (13.0%) and slow waves (52.2%). Brain lesions on MRI recognized mainly in the limbic system (65.2%), thalamus (39.1%), midbrain (39.1%), and cerebellum (30.4%). Treatment included intravenous methylprednisolone (91.3%), immunoglobulin (39.1%), cyclophosphamide (30.4%), and rituximab (17.4%). Median hospital stay was 38 days. There was one case (4.3%) of death. There was no considerable clinical difference between encephalitis with positive and negative NMDAR-antibody. Conclusion: NMDAR-antibody encephalitis has been an emerging disease with an increasing number of new cases. Early immunotherapy when NMDAR-antibody encephalitis is suspected should be of consideration.

Article Details

Keywords

NMDAR-antibody encephalitis, children

References

[1] Scheer S, John RM. Anti-N-Methyl-D-Aspartate Receptor Encephalitis in Children and Adolescents. J Pediatr Health Care. 2016;30(4):347–58.
[2] Goldberg EM, Titulaer M, de Blank PM, Sievert A, Ryan N. Anti–N-methyl-D-aspartate Receptor-Mediated Encephalitis in Infants and Toddlers: Case Report and Review of the Literature. Pediatr Neurol. 2014 Feb;50(2):181–4.
[3] Ryan N. Anti-N-Methyl-d-Aspartate Receptor-Mediated Encephalitis: Recent Advances in Diagnosis and Treatment in Children. Curr Probl Pediatr Adolesc Health Care. 2016 Feb;46(2):58–61.
[4] Hacohen Y, Wright S, Waters P, Agrawal S, Carr L, Cross H, et al. Paediatric autoimmune encephalopathies: Clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry. 2013;84(7):748–55.
[5] Gong X, Wang N, Zhu H, Tang N, Wu K, Meng Q. Anti-NMDAR antibodies, the blood–brain barrier, and anti-NMDAR encephalitis. Front Neurol [Internet]. 2023 Dec 8;14. Available from: https://www.frontiersin.org/articles/10.3389/fneur.2023.1283511/full
[6] Armangue T, Titulaer MJ, Málaga I, Bataller L, Gabilondo I, Graus F, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr. 2013;162(4):850-856.e2.
[7] N. FR, J. D. Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. Curr Opin Pediatr. 2010;22(6):739–44.
[8] Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The Frequency of Autoimmune N-Methyl-D-Aspartate Receptor Encephalitis Surpasses That of Individual Viral Etiologies in Young Individuals Enrolled in the California Encephalitis Project. Clinical Infectious Diseases [Internet]. 2012 Apr 1;54(7):899–904.
[9] Wright S, Hacohen Y, Jacobson L, Agrawal S, Gupta R, Philip S, et al. N-methyl-D-aspartate receptor antibody-mediated neurological disease: Results of a UK-based surveillance study in children. Arch Dis Child. 2015;100(6):521–6.
[10] Nguyen Thi Hoang M, Nguyen Hoan P, Le Van T, McBride A, Ho Dang Trung N, Tran Tan T, et al. First reported cases of anti-NMDA receptor encephalitis in Vietnamese adolescents and adults. J Neurol Sci [Internet]. 2017 Feb;373:250–3.
[11] Nosadini M, Thomas T, Eyre M, Anlar B, Armangue T, Benseler SM, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm [Internet]. 2021 Sep;8(5).
[12] Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol [Internet]. 2018 Jan;83(1):166–77.
[13] Garg D, Mohammad SS, Sharma S. Autoimmune Encephalitis in Children: An Update. Indian Pediatr [Internet]. 2020 Jul 29;57(7):662–70.
[14] de Bruijn MAAM, Bruijstens AL, Bastiaansen AEM, van Sonderen A, Schreurs MWJ, Sillevis Smitt PAE, et al. Pediatric autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm [Internet]. 2020 May;7(3).
[15] Yakir MJ, Yang JH. Treatment Approaches in Pediatric Relapsing Autoimmune Encephalitis. Curr Treat Options Neurol [Internet]. 2024 May 21;26(5):139–49.
[16] Erickson TA, Muscal E, Munoz FM, Lotze T, Hasbun R, Brown E, et al. Infectious and Autoimmune Causes of Encephalitis in Children. Pediatrics [Internet]. 2020 Jun 1;145(6)